1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Marketing & Advertising

IRS Notice Pushes Perrigo's Potential Tax Debt From Move To Ireland Close To $3bn

 
• By Malcolm Spicer

IRS tax assessment for 2013, the year Perrigo acquired Dublin-based Elan, adds another cloud to OTC private label giant's outlook as it prepares to present plans for accelerating growth for its long-slumping consumer health business in the US and Europe at a March 9 investor day conference. Perrigo shares dropped more than 9% in early trading after IRS notice became known to investors before inching upward and ending at $47.92, down 6.8% from the previous day's close.

IRS bulding sign

Perrigo Co. PLC's potential tax debt linked to its move to become an Irish firm could reach nearly $3bn with the US Internal Revenue Service ordering a $843m payment on top of Ireland's recent $1.9bn assessment.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Marketing & Advertising

Alfasigma Seeking Slice Of EU’s Largest OTC Market With German Launch

 
• By Tom Gallen

Italy's Alfasigma has expanded its operation in Germany with the creation of a new Consumer Healthcare unit. Led by Rüdiger Hoppe, the business is rolling out OTC medical devices and dietary supplements in the gastrointestinal category.

Maxwellia Launches UK TV Campaign For Evana Showing Reality Of Menstruation

 
• By David Ridley

Maxwellia's “bold, honest, and completely unfiltered” campaign for Evana menstrual health brand tells the story of a woman dealing with the realities of a heavy period, showing “real blood, real leaks.”

Haleon Launches ‘Prescription Strength’ Hayfever Remedy In The UK

 
• By David Ridley

Pirilieve Hayfever Relief Tablets contain 120mg fexofenadine hydrochloride, which the firm notes is an active ingredient that was “previously only available behind pharmacy counters.”

Haleon’s US Eroxon Launch Falls Short Of Expectations

 
• By Tom Gallen

Consumer uptake of Eroxon - the first FDA-approved OTC ED treatment available in the US - has been slower than expected, according to Haleon, which says its working with retailers to build awareness.

More from Business

Pharma Still Nervous While Riding Trump’s Tariff Rollercoaster

 
• By Jessica Merrill

The rollout of Trump’s plan has been a policy whiplash, but despite a 90-day pause on tariffs, the US president still appears to be holding a grudge with industry over drug pricing.

KKR Expands Health & Beauty Portfolio With Deal For Sweden’s Karo

 
• By Tom Gallen

Consumer health player Karo is changing hands from EQT to KKR in a deal thought to value the Stockholm-based firm at over €2.5bn.

‘The Only Certainty Is Uncertainty’ In The UK’s Consumer Health Market

 
• By David Ridley

While uncertainty might reign in the UK consumer health market - which grew by by 8% to £4.1bn ($5.3bn) in 2024 - “opportunity is everywhere” according to NielsenIQ health and beauty insights manager Alex Heffernan.